Cellular Biomedicine Group Reports First Quarter 2018 Financial Results and Highlights Operational Progress
Cellular Biomedicine (NASDAQ:CBMG) a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported financial results and business highlights for the first quarter ended March 31, 2018. As quoted in the press release: “Early in 2018, we’ve made notable progress with our immuno-oncology platform as the …
Cellular Biomedicine (NASDAQ:CBMG) a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported financial results and business highlights for the first quarter ended March 31, 2018.
As quoted in the press release:
“Early in 2018, we’ve made notable progress with our immuno-oncology platform as the China Food and Drug Administration (CFDA) accepted the Company’s Investigational New Drug Applications (IND) for “C-CAR011” anti-CD19 chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with B-cell Non-Hodgkin’s lymphoma (NHL) and acute lymphoblastic leukemia (ALL),” commented Tony Liu, Chief Executive Officer of CBMG. “We are advancing recognized CAR-T therapies through China’s regulatory pathway, with our state of the art GMP facility, which houses a CBMG-GE Healthcare China joint innovation center, and a CBMG-Thermo Fisher Scientific joint innovation center.
“The recent investment from Sailing Capital Overseas Investment Ltd., of $30.6 million, will enable further clinical development by funding our current multiple clinical programs, as well as expanding our immuno-oncology pipeline with further CAR-T receptor constructs for various liquid and solid tumor indications, including, but not limited to, Anti-BCMA CAR for multiple myeloma (MM). We continue to focus on accelerating deployment of new cell therapies to the clinical stage, confident in our in-house research and development capabilities, our CMC platform, and our broad clinical development network with leading medical institutions in China.”
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 1827.54 | +0.47 | |
Silver | 21.15 | +0.03 | |
Copper | 3.74 | 0.00 | |
Palladium | 1879.51 | +6.50 | |
Platinum | 911.26 | +4.32 | |
Oil | 107.06 | +2.79 | |
Heating Oil | 4.24 | +0.02 | |
Natural Gas | 6.17 | -0.07 |
DOWNLOAD FREE REPORTS
BROWSE COMPANIES BY SECTOR
- Agriculture Investing
- Phosphate Investing
- Potash Investing
- Base Metals Investing
- Copper Investing
- Iron Investing
- Lead Investing
- Nickel Investing
- Zinc Investing
- Battery Metals Investing
- Cobalt Investing
- Graphite Investing
- Lithium Investing
- Manganese Investing
- Vanadium Investing
- Critical Metals Investing
- Magnesium Investing
- Rare Earth Investing
- Scandium Investing
- Tantalum Investing
- Tellurium Investing
- Tungsten Investing
- Energy Investing
- Oil and Gas Investing
- Uranium Investing
- Gem Investing
- Diamond Investing
- Industrial Metals Investing
- Aluminum Investing
- Chromium Investing
- Coal Investing
- Molybdenum Investing
- Tin Investing
- Precious Metals Investing
- Gold Investing
- Palladium Investing
- Platinum Investing
- Silver Investing
- 3D Printing Investing
- Bitcoin Investing
- Blockchain Investing
- Cleantech Investing
- Cloud Investing
- Cryptocurrencies
- Data Investing
- Emerging Tech Investing
- Artificial Intelligence Investing
- Mobile Investing
- Robotics Investing
- Fintech Investing
- Gaming Investing
- Esports Investing
- Nanoscience Investing
- Graphene Investing
- Nanotech Investing
- Security Investing
Featured stocks
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.